Whats new
Whats new.
Jefferies - To Initiate TACTI-004 Phase 3 Trial in 1L NSCLC; Rated Buy, Raise PT to A$2 (Analyst: Dr David Stanton)
December 9th 2024
For a copy of this research report please contact your Jefferies advisor
Whats new
December 9th 2024
For a copy of this research report please contact your Jefferies advisor